The new technology from University of Houston could make any mask more resistant to viruses. Photo courtesy of Seamus Curran/Integricote

The start of 2020, though most didn't know it at the time, meant a huge change to society. Though coronavirus didn't yet seem to be an issue for the United States, the world was entering into a new normal where wearing face masks in public is common and necessary to prevent the spread of COVID-19.

"We left normal in December," says Seamus Curran, a professor of physics at the University of Houston, "and, when everyone was planning their New Year's resolutions, little did we know that the old normal of before is gone. None of us saw that life passing away — and it was taken away by a bug 1,000 times smaller than lice. And like lice, it's going to be with us for a long time."

To that end, Curran, who is well-known for his work commercializing nanotechnologies, is pulling from his past to deal with a future demand. The professor is using a hydrophobic coating he developed nearly 10 years ago to improve the ability of surgical masks to protect against transmission of the virus.

It's no secret that good face masks are a dire, worldwide need. But Curran notes that standard masks are "somewhat porous, and especially if they get wet, they can allow the virus to penetrate." People infected with the virus, he adds, could spread it even through a mask, while people who aren't sick could still become infected, despite wearing a less-protective mask.

Curran calls N95 masks, "the gold standard, able to filter very small particles and offering better protection than standard surgical masks." But he notes that they are hard to manufacture, and global demand is for tens of millions of items. His work will make masks impervious to water, thus improving protection, he explains.

That means those who already own masks are in luck: Curran's team is planning to sell spray for the hydrophobic coatings so that people can apply it themselves at home or at work. "However, it's cheaper and far more effective to be able to apply it in large batch quantities that manufacturers can do," Curran adds.

The globally minded Curran has only one local requirement: "We will only sell to U.S. manufacturers that manufacture here in the U.S. It's not a limiting factor and may change in the future, but right now, I have to deal with my community here in Houston, Texas, and the U.S. It has to be my priority."

University of Houston's Dr. Seamus Curran. Photo courtesy of University of Houston

Curran and his team are working though the process to make sure their coatings are compliant with all federal rules. "Sometimes, this is making sure your materials are registered and allowed," he says. "Sometimes it's making sure the products follow relevant EPA and FDA guidelines. However, we are very close, as in weeks, and not some arbitrary academic timeline in the distant future."

He first launched a nanotechnology business in 2013, according to UH. His company, Integricote, based at the UH Technology Bridge, focuses on manufacturing sealers for masonry, wood, and concrete. The professor has developed nanotech coatings for fabrics since 2011, technology that he now is using to demonstrate a way to provide more protection against SARS and COVID-19.

Curran, who often says he hates to "play defense," hopes to get a jump on the virus spread with his new technology and take a proactive approach to a long-term issue. "Remember, H1N1 affected 61 million Americans and 12,500 people died from it between 2009 and 2010," he notes. "Do we think that's it? Did we think Ike was the last big hurricane to hit us, or do we expect more? Yet, we have compensated for this and found a way to be resilient and have a normal life."

Technical and scientific in his work, the passionate professor says he is galvanized by a simple, primal motive. "This is personal, this virus has threatened my family and I'm not sitting back, ideally, just letting this happen," Curran says. "I'm just like any other husband, father, son, brother, and uncle: I will do all I can to protect those dearest to me and I will not have it any other way."

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from leaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”